Board summary
Key figures
45,138
Registered population
65.2% aged 18–64
12.9%
Aged 65+
ICB 19.0% · England 17.9%
26.3%
Ethnic minority (non-White)
7.3% Asian · England 9.6%
77.3%
In IMD quintile 1
ICB 31.9% · England 21.0%
~27,404
Core20 residents (est.)
Resident basis; registered basis ~35,224 · see page 3
6,021
Hypertension register
-1.18% in 3 yrs · England +5.60%
812
SMI register
9.7% of Liverpool (LAD)'s
1,314
COPD register
Reviews -1.79% in 3 yrs
Forecast to 2030
6,278
Hypertension patients, 2030
+257 on today
73.2%
QRISK ≥20% on statins, 2030
+2.69pp over 3 yrs
2.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cervical screening aged 25-49 trails all benchmarks.
Coverage at 52.7% is 14.1 pp below England (66.8%) and fell 3.9% over 2023 to 2025, which may reflect recall gaps to audit.
Age-five second MMR dose lags national target.
In Q1 2025/26, coverage is 63.7% (England 82.8%), 31.3 pp below the 95.0% target and 20 pp below first-dose coverage at 83.7%.
Asthma review coverage exceeds national and local rates.
Annual reviews reach 77.2% (England 65.7%; Liverpool 64.3%; ICB 62.3%), though about 610 of 2,691 register patients remain unreviewed for targeted recall.
Population, age and ethnicity
A younger population with 12.9% aged 65+ and 26.3% ethnic minority residents
Across 45,138 registered patients, the PCN has a younger profile: 12.9% are aged 65+, below Liverpool (LAD) (15.6%), NHS Cheshire and Merseyside ICB (19.0%) and England (17.9%), while 21.9% are aged 0-17 (Liverpool LAD 19.8%; ICB 19.2%; England 19.6%). Census data shows a 73.7% White resident share, lower than Liverpool (LAD) (84.0%), the ICB (93.0%) and England (81.1%), giving a 26.3% non-White share. ONS projections indicate 3.9% list growth to 2030 (Liverpool LAD 3.0%; ICB 2.3%; England 2.3%). This profile may direct demand toward paediatric access and adapted prevention; projection methods remain unverified.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Liverpool LA) | 3,035 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 50.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Liverpool LA) | 1,652 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Liverpool LA) | 27.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
With 77.3% Core20 patients, deprivation is high and spans 36.0 pp between practices
The PCN average IMD decile is 2.2, compared to 3.4 in Liverpool (LAD), 5.2 in NHS Cheshire and Merseyside ICB and 5.5 in England. Registered patients in the Core20 cohort reach 77.3% (Liverpool LAD 54.9%; ICB 31.9%; England 21.0%). Practice shares span 36.0 pp, from 53.94% at Sefton Park Medical Centre to 89.92% at Picton Green. Beacon Health Kensington holds the largest Core20 volume at an estimated 8,400 patients. Practice estimates total 35,224, differing from the resident decile 1+2 estimate of 27,404.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
812
SMI register
1.75% recorded prevalence
297
Learning disability register
0.64% recorded prevalence
14
Care homes, 578 beds
In the PCN catchment
10.3%
Provide unpaid care
Liverpool (LAD), Census 2021
Severe mental illness prevalence is 1.8% (812 patients), above Liverpool (LAD) (1.4%), NHS Cheshire and Merseyside ICB (1.1%) and England (1.0%), while learning disability prevalence is 0.6% (297 patients; LAD 0.6%; ICB 0.6%; England 0.6%). Catchment data records 14 care homes and 578 beds, though resident occupancy is unconfirmed. With SMI register prevalence above Liverpool, ICB and England rates, annual physical-health checks for this group could be an essential workload.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.8% (England 1.0%). Recorded blood pressure checks reach 80.1% (England 83.4%) and BMI checks 79.6% (England 82.1%). SMI physical health checks trail national rates, which local audit could test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,021
Hypertension register
−1.18%
Register growth, 3 yrs
Liverpool (LAD) +2.01% · England +5.60%
+0.40pp
BP control, under 80
≤140/90 · −0.60pp aged 80+
+257
More patients by 2030
Forecast 6,278 (12.68%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.0% (6,021 patients), below Liverpool (LAD) (14.0%), NHS Cheshire and Merseyside ICB (16.8%), and England (15.2%), with three-year prevalence change at -1.2% (England +5.6%). Blood pressure control for patients under 80 is 61.4%, trailing Liverpool (LAD) (67.0%), the ICB (66.4%), and England (67.8%). Across practices, recorded prevalence spans from 9.4% at Picton Green to 17.3% at Green Lane Medical Centre. Lower blood pressure control than national benchmarks may indicate review or treatment escalation gaps, which clinical audit across member practices could test.
Lipids and statins
For patients with QRISK >= 20%, lipid-lowering therapy reaches 67.5%, above Liverpool (LAD) (65.6%), NHS Cheshire and Merseyside ICB (63.2%), and England (63.6%). Higher therapy coverage than England is consistent with strong primary prevention that the PCN could sustain through routine annual medication recalls.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 75,891 | £1.50 | £1.71 | £1.86 | £113,836 |
| Cardiovascular (all), 2025 | 105,172 | £3.70 | £4.37 | £3.33 | £389,136 |
In 2026, the PCN prescribed 75,891 lipid-regulating items at £1.50 per item, below Liverpool (LAD) (£1.82), NHS Cheshire and Merseyside ICB (£1.71), and England (£1.86), spending £27,321 less than at England's unit cost. Lower unit cost than national benchmarks provides a baseline for review, though unit cost does not measure efficiency or formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.14%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.39%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.8% (1,314 patients), above England (1.9%) and NHS Cheshire and Merseyside ICB (2.5%) but below Liverpool (LAD) (3.0%), with three-year change of -5.0% (England +2.6%). Asthma prevalence is 6.2% (2,691 patients; England 6.6%). Annual reviews exceed England for COPD (83.6% vs 76.4%) and asthma (77.2% vs 65.7%), though an estimated 614 asthma patients lacked a recorded review. Prescribing of 2,215 asthma items per 1,000 aged 5-19 (England 1,488 rate) may reflect elevated need, which local audit could test.
Cancer register and children's immunisation
Cancer prevalence is 2.7% (1,264 patients), below England (3.8%). At 24 months, MMR dose 1 coverage is 70.5%, below England (88.3%) and the 95.0% target. At age 5, MMR dose 2 is 63.7% (England 82.8%), trailing dose 1 (83.7%) by 20 pp across the PCN and by 40 pp at Beacon Health Kensington. This cross-sectional difference may reflect recall gaps that practice audit could test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of staged cancers (7,482 of 13,490) across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2, compared with 55.3% in England and 19.5 pp below the 75.0% national ambition by 2028. Known-stage coverage was 72.8% (13,490 of 18,522). Reaching 75.0% requires about 2,640 extra early-stage diagnoses annually across the ICB. These system figures do not reflect PCN performance. Within the PCN, cervical screening coverage in women aged 25-49 is 52.7%, trailing England (66.8%) and Liverpool (60.4%), falling 3.9% over three years (England -1.0%), with Beacon Health Kensington at 39.2%. Lagging screening uptake risks delayed detection, warranting targeted practice recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional data for Jul 2026, Liverpool Women's NHS Foundation Trust achieved 69.1% on the 62-day referral to treatment standard (19 of 27.5 pathways), trailing the 85.0% standard, Liverpool University Hospitals NHS Foundation Trust (73.3%), England (71.2%) and NHS Cheshire and Merseyside Integrated Care Board (76.2%). The 28-day faster diagnosis standard reached 75.7% (operational standard 75.0%; England 79.3%). For non-obstetric ultrasound, 6.1% of patients waited 6+ weeks, compared with 4.4% at Liverpool University Hospitals NHS Foundation Trust and 19.6% across England. These provider figures describe secondary care rather than PCN performance. Provider treatment delays could affect patient outcomes across referred.
| Pathways within standard (%) | Liverpool Women's | Liverpool | Mersey and West Lancashire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.73 | 75.47 | 72.39 | 77.25 | 79.32 |
| 31-day treatment (96%) | 85.42 | 90.51 | 95.46 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 69.09 | 73.26 | 77.96 | 76.23 | 71.16 |
| Community services activity | Liverpool residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 127,380 | 541,280 |
| Referrals | 15,675 | 97,150 |
| Patients with a contact | 24,970 | 146,240 |
Community services (residents of Liverpool), Jun 2026 (provisional). In provisional Jun 2026 community data, Liverpool residents aged 65 and over accounted for 65.4% of borough contacts (83,300 of 127,380). This captures borough-level activity rather than PCN caseload. Substantial older-age borough community demand underscores the need for close system coordination.
Practice variation and patient experience
Practice QOF and vaccination achievement vary widely alongside marked deprivation and low survey response
In 2025/26, overall QOF achievement reached 79.7% at Beacon Health Kensington, and 89.5% at Dunstan Village Group Practice and Sefton Park Medical Centre (England 92.5%). Vaccination and immunisation achievement spanned 12.2 pp, from 15.6% at Beacon Health Kensington to 27.8% at Earle Road Medical Centre (England 55.2%). Points do not establish population reach.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Green Lane | 125 | 77.0 | 58.8% | 73.4% | 86.9% |
| Sefton Park | 93 | 53.9 | 70.9% | 70.6% | 86.2% |
| Dunstan Village | 78 | 87.8 | 47.8% | 82.7% | 82.8% |
| Earle Road | 73 | 87.4 | 34.2% | 57.2% | 74.8% |
| Picton Green | 95 | 89.9 | 48.9% | 71.5% | 73.6% |
| Beacon Health | 88 | 87.1 | 50.9% | 70.2% | 68.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
19 of 25 measures trail England's three-year change, led by clinical reviews
Across 25 compared measures, 19 trail England's three-year change. Heart failure reviews fell 1.2% (England +8.7%), psychosis alcohol recording fell 2.0 pp (England +5.4 pp), and COPD reviews fell 1.8% (England +2.8%). Conversely, breast screening rose 13.9% (England +8.4%) and non-frail diabetes HbA1c control rose 5.8% (England +4.4%). These diverging trajectories could reflect selective recall or escalation gaps across long-term condition pathways, which local audit can test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD register
Alcohol record (psychosis)
Hypertension register
Stroke register
Breast screening (53-70)
Diabetes HbA1c control
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Liverpool (LAD) | Asset | PCN | Liverpool (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (578 beds) | n/a | Schools (catchment) | 114 | n/a |
| Children's centres | 4 | 26 | Places of worship | 74 | 240 |
| Libraries | 4 | 17 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 20 | 91 | Primary academies | 4 | 20 |
| Special schools | 2 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review catch-up
Annual asthma review coverage is 77.2% (above England 65.7%, Liverpool 64.3% and ICB 62.3%), yet applying this rate to the 2,691 register leaves 614 (about 610) patients unreviewed. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Childhood MMR and pre-school recall
At 24 months (112 children), MMR1 is 70.5% (24.5 pp below 95.0%; England 88.3%). At age 5 (135 children), MMR2 is 63.7% (20 pp below MMR1 at 83.7%, and 40 pp below at Beacon Health Kensington). Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Cervical screening and early diagnosis
PCN cervical screening (aged 25-49) is 52.7% (England 66.8%; Liverpool 60.4%), falling 3.9% (England -1.0%), and 39.2% at Beacon Health Kensington. ICB early-stage cancer is 55.5% (19.5 pp below 75.0%). Low cost, quick to run.
Evidence base: the cancer register is the cohort for breast, bowel and cervical screening and for urgent suspected-cancer referral; where patients present as emergencies, the screening and referral steps have failed and symptom awareness needs support.
Policy anchor: Core20PLUS5 — 75% of cancers diagnosed at stage 1 or 2 by 2028.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored access review (p2) | White | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| MMR second dose recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Asthma annual review catch-up (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Childhood MMR and pre-school recall (p12) | MMR dose 1 coverage at 24 months · 6-in-1 complete primary course at 24 months · MMR dose 1 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Cervical screening and early diagnosis (p12) | Cancer register · Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) · Cancers diagnosed at stage 1 or 2 (All cancer sites) | Core20PLUS5, 75% stage 1–2 by 2028 | PCN & Practice & ICB |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
